EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review

Annik Caliezi iD, Aref Hosseini, Ronald Wolf iD, Seyed Morteza Seyed Jafari

Journal of Clinical Medicine · 11.04.2026 · 15 (8) · 2909

DOI: 10.3390/jcm15082909 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.04.2026. Verfasst von Annik Caliezi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Foundation for medical-biological Research, Department of Dermatology Inselspital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients with HS, including on their cardiovascular risk and quality of life.

Methods

A literature search was conducted on Embase and PubMed, yielding 300 papers, of which 10 were used for this review.

Results

HS patients using GLP-1 agonists showed improved clinical course with less pain and suppuration. Further, patients’ quality of life and mental health improved and their cardiovascular risk was reduced. Inflammatory parameters showed no significant changes. Patients receiving a higher drug dose of GLP-1 agonists were more likely to show clinical improvement. A reduction in weight or BMI did not correlate with improvements in Hurley stage, pain or depression. Hence, HS patients could be treated with GLP-1 agonists.

Conclusions

Therefore, whether patients’ improvement is due to weight loss, or other mechanisms, i.e., GLP-1 agonists’ anti-inflammatory properties, remains to be determined in further studies.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular riskeffectsglucagon like peptide 1 receptor agonistshidradenitis suppurativaquality of life

Autor:innen und Institutionen

  • Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland.
  • Institute of Pharmacology, University of Bern, Rosenbühlgasse 27, 3010 Bern, Switzerland.

ORCID-Profile: Annik Caliezi, Ronald Wolf

Förderung

  • Novartis Foundation for medical-biological Research
  • Department of Dermatology Inselspital

Zitieren

APA

Caliezi, A., Hosseini, A., Wolf, R., & Seyed Jafari, S. M. (2026). Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review. Journal of Clinical Medicine, 15(8), 2909. https://doi.org/10.3390/jcm15082909

Vancouver

Caliezi A, Hosseini A, Wolf R, Seyed Jafari SM. Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review. Journal of Clinical Medicine. 2026;15(8):2909. doi:10.3390/jcm15082909

BibTeX
@article{Caliezi2026,
  author = {Caliezi, Annik and Hosseini, Aref and Wolf, Ronald and Seyed Jafari, Seyed Morteza},
  title = {Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {2909},
  doi = {10.3390/jcm15082909}
}
Kostenlos starten →